Large study links semaglutide use to 49% lower COVID-19 mortality risk

In the long human struggle to understand which tools of medicine carry benefits beyond their intended purpose, a study of more than ten million people has surfaced a striking association: those taking semaglutide, the widely prescribed GLP-1 drug, faced roughly half the risk of dying from COVID-19 compared to those who did not. Researchers at the University of California, San Francisco drew this finding from real-world insurance claims spanning a year of the pandemic's chronic phase, a period when the virus had not relented but the world had begun to adapt. The result echoes earlier clinical t